Ventripoint Diagnostics Stock Current Valuation
| VPTDF Stock | USD 0.10 0 1.42% |
Valuation analysis of VentriPoint Diagnostics helps investors to measure VentriPoint Diagnostics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that VentriPoint Diagnostics' price fluctuation is out of control at this time. Calculation of the real value of VentriPoint Diagnostics is based on 3 months time horizon. Increasing VentriPoint Diagnostics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the VentriPoint otc stock is determined by what a typical buyer is willing to pay for full or partial control of VentriPoint Diagnostics. Since VentriPoint Diagnostics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of VentriPoint OTC Stock. However, VentriPoint Diagnostics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.1 | Real 0.0921 | Hype 0.1 | Naive 0.0933 |
The real value of VentriPoint OTC Stock, also known as its intrinsic value, is the underlying worth of VentriPoint Diagnostics OTC Stock, which is reflected in its stock price. It is based on VentriPoint Diagnostics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of VentriPoint Diagnostics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of VentriPoint Diagnostics helps investors to forecast how VentriPoint otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of VentriPoint Diagnostics more accurately as focusing exclusively on VentriPoint Diagnostics' fundamentals will not take into account other important factors: VentriPoint Diagnostics OTC Stock Current Valuation Analysis
VentriPoint Diagnostics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current VentriPoint Diagnostics Current Valuation | 28.27 M |
Most of VentriPoint Diagnostics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, VentriPoint Diagnostics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, VentriPoint Diagnostics has a Current Valuation of 28.27 M. This is 99.8% lower than that of the Healthcare sector and 99.77% lower than that of the Medical Devices industry. The current valuation for all United States stocks is 99.83% higher than that of the company.
VentriPoint Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses VentriPoint Diagnostics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of VentriPoint Diagnostics could also be used in its relative valuation, which is a method of valuing VentriPoint Diagnostics by comparing valuation metrics of similar companies.VentriPoint Diagnostics is currently under evaluation in current valuation category among its peers.
VentriPoint Fundamentals
| Return On Equity | -1.35 | |||
| Return On Asset | -0.64 | |||
| Operating Margin | (124.50) % | |||
| Current Valuation | 28.27 M | |||
| Shares Outstanding | 156.51 M | |||
| Shares Owned By Insiders | 1.75 % | |||
| Price To Earning | 68.00 X | |||
| Price To Book | 8.27 X | |||
| Price To Sales | 897.04 X | |||
| Gross Profit | (6.27 K) | |||
| EBITDA | (3.82 M) | |||
| Net Income | (3.88 M) | |||
| Cash And Equivalents | 7.29 M | |||
| Cash Per Share | 0.05 X | |||
| Total Debt | 125.38 K | |||
| Debt To Equity | 0.02 % | |||
| Current Ratio | 6.74 X | |||
| Book Value Per Share | 0.03 X | |||
| Cash Flow From Operations | (3.15 M) | |||
| Earnings Per Share | (0.02) X | |||
| Number Of Employees | 17 | |||
| Beta | 0.28 | |||
| Market Capitalization | 32.09 M | |||
| Total Asset | 9.54 M | |||
| Retained Earnings | (20.43 M) | |||
| Working Capital | (1.99 M) | |||
| Current Asset | 1.07 M | |||
| Current Liabilities | 3.05 M | |||
| Net Asset | 9.54 M |
About VentriPoint Diagnostics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze VentriPoint Diagnostics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of VentriPoint Diagnostics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of VentriPoint Diagnostics based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in VentriPoint OTC Stock
VentriPoint Diagnostics financial ratios help investors to determine whether VentriPoint OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in VentriPoint with respect to the benefits of owning VentriPoint Diagnostics security.